S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
The single greatest medical breakthrough of all time? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
The single greatest medical breakthrough of all time? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
The single greatest medical breakthrough of all time? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
The single greatest medical breakthrough of all time? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Forecast, Price & News

$8.04
+0.10 (+1.26%)
(As of 09/22/2023 ET)
Compare
Today's Range
$7.81
$8.18
50-Day Range
$7.47
$10.84
52-Week Range
$1.52
$11.45
Volume
172,045 shs
Average Volume
211,159 shs
Market Capitalization
$243.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Lifecore Biomedical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
18.2% Upside
$9.50 Price Target
Short Interest
Bearish
6.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Lifecore Biomedical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to $0.58 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

887th out of 965 stocks

Pharmaceutical Preparations Industry

425th out of 456 stocks


LFCR stock logo

About Lifecore Biomedical (NASDAQ:LFCR) Stock

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is based in Chaska, Minnesota.

LFCR Price History

LFCR Stock News Headlines

Lifecore Biomedical (NASDAQ: LFCR)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Q4 2023 Lifecore Biomedical Inc Earnings Call
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
Lifecore Biomedical Inc.
See More Headlines
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

LFCR Company Calendar

Last Earnings
8/31/2023
Today
9/24/2023
Next Earnings (Estimated)
10/05/2023
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LFCR
Employees
689
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+18.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-102,190,000.00
Pretax Margin
-59.59%

Debt

Sales & Book Value

Annual Sales
$103.27 million
Cash Flow
$4.14 per share
Book Value
$3.08 per share

Miscellaneous

Free Float
25,892,000
Market Cap
$243.77 million
Optionable
Optionable
Beta
1.13
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. James G. Hall (Age 60)
    CEO, Pres & Director
    Comp: $711.57k
  • Mr. John D. Morberg (Age 59)
    Exec. VP & CFO
    Comp: $443.43k
  • Dr. Albert D. Bolles Ph.D. (Age 65)
    Pres of Curation Foods, Inc.
    Comp: $688.19k
  • Mr. Steve W. Laninga
    VP of Operations
  • Dr. Kipling Thacker Ph.D. (Age 68)
    VP & Chief Scientist
  • Mr. Aaron Perlitsh
    Director of Internal Audit & Chief Compliance Officer
  • Mr. Darren M. Hieber
    Sr. VP of Corp. Devel. & Partnerships
  • Ms. Kara Morley
    Sr. VP of HR
  • Ms. Jackie Q. Klecker
    Exec. VP & GM
  • Mr. Matt Augustson
    Sr. VP of Information Technology













LFCR Stock - Frequently Asked Questions

Should I buy or sell Lifecore Biomedical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LFCR shares.
View LFCR analyst ratings
or view top-rated stocks.

What is Lifecore Biomedical's stock price forecast for 2023?

2 Wall Street analysts have issued 1-year target prices for Lifecore Biomedical's shares. Their LFCR share price forecasts range from $9.00 to $10.00. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price.
View analysts price targets for LFCR
or view top-rated stocks among Wall Street analysts.

How have LFCR shares performed in 2023?

Lifecore Biomedical's stock was trading at $6.48 at the beginning of 2023. Since then, LFCR stock has increased by 24.1% and is now trading at $8.04.
View the best growth stocks for 2023 here
.

When is Lifecore Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 5th 2023.
View our LFCR earnings forecast
.

How were Lifecore Biomedical's earnings last quarter?

Lifecore Biomedical, Inc. (NASDAQ:LFCR) issued its earnings results on Thursday, August, 31st. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.82. The firm had revenue of $31.55 million for the quarter, compared to the consensus estimate of $28.99 million. Lifecore Biomedical had a negative net margin of 71.36% and a negative trailing twelve-month return on equity of 79.34%.

What is Lifecore Biomedical's stock symbol?

Lifecore Biomedical trades on the NASDAQ under the ticker symbol "LFCR."

Who are Lifecore Biomedical's major shareholders?

Lifecore Biomedical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wynnefield Capital Inc. (16.24%), Cove Street Capital LLC (5.34%), BlackRock Inc. (1.75%), Visionary Wealth Advisors (1.65%), Geode Capital Management LLC (0.95%) and Royal Bank of Canada (0.48%).

How do I buy shares of Lifecore Biomedical?

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lifecore Biomedical's stock price today?

One share of LFCR stock can currently be purchased for approximately $8.04.

How much money does Lifecore Biomedical make?

Lifecore Biomedical (NASDAQ:LFCR) has a market capitalization of $243.77 million and generates $103.27 million in revenue each year. The company earns $-102,190,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Lifecore Biomedical have?

The company employs 689 workers across the globe.

How can I contact Lifecore Biomedical?

Lifecore Biomedical's mailing address is 2811 AIRPARK DRIVE, SANTA MARIA CA, 93455. The official website for the company is www.lifecore.com. The company can be reached via phone at (800) 454-1355, via email at jeff.sonnek@icrinc.com, or via fax at 650-368-9818.

This page (NASDAQ:LFCR) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -